Alzheimer's Disease Market to Reach $13.7 Billion by 2030, Says Report

The expansion of Alzheimer’s disease market is credited to the launch of revolutionary treatments aimed at addressing the challenges presented by Alzheimer's.

In 2030, the Alzheimers disease (AD) market is expected to rise at a compound annual growth rate of 20%, $13.7 billion ().

The growth will be particularly seen across the eight major markets such as the US, France, Germany, //Italy, Spain, the UK, Japan, and China.

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

‘Leqembi and donanemab the drugs used to treat Alzheimer’s could generate sales of $2.0 billion in 2030.’

The report, "Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update", reveals that the main driver of growth will be the launch of 23 new pipeline products, including novel symptomatic therapies for the treatment of agitation associated with the neurological disorder and the entry of disease-modifying therapies (DMTs) to the market.

Alzheimer's Disease Market

"In 2020, the competitive landscape in Alzheimer's disease only offered medications such as acetylcholinesterase inhibitors, which are aimed at treating the symptoms of the disease," said Philippa Salter, Neurology Analyst at GlobalData, in a statement.

"These drugs are modestly effective and primarily off patent, thus creating significant opportunity for new entrants into the Alzheimer's market," she added.

A major focus of R&D in the Alzheimer's therapeutic space is preventing the accumulation of amyloid beta and formation of amyloid beta plaques in the brain.

Quiz On Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.

Drug developers have finally begun to see some success with this strategy, first with the FDA approval of Biogen's anti-amyloid beta monoclonal antibody (mAb) Aduhelm (aducanumab) in 2021, followed by the FDA approval of Eisai/Biogen's anti-amyloid beta mAb Leqembi (lecanemab) in January 2023.

The launch of these products and two other anti-amyloid beta mAbs, Lilly's donanemab and remternetug, during the forecast period will be a significant driver of growth within the Alzheimer's market.

Alzheimer's Risk Assessment Calculator
Alzheimer’s Risk Assessment Calculator is a tool to measure the level of Alzheimer’s disease. It also provides tips to prevent Alzheimer’s disease.

According to Salter, Leqembi and donanemab have both demonstrated that they can reduce cognitive decline in Phase III clinical trials. As such, they are expected to become the top-selling Alzheimer'sAdrugs by 2030.

While the AD market is projected to experience strong growth, challenges remain.

Caring for Alzheimers disease patients
Alzheimer's disease is a complex brain disorder that triggers the most common form of dementia. The slide show will show how patients need support and care as dementia progresses.

The rates of diagnosis and treatment are low across all stages of the disease, so there is an unmet need for accurate, easy-to-use diagnostic tests, and for biomarkers that can be used for patient classification and the assessment of treatment response, the report said.

Reference:

Global Alzheimer’s disease market to reach $13.7bn in 2030 driven by novel drug launches - (https://www.globaldata.com/media/pharma/global-alzheimers-disease-market-to-reach-13-7bn-in-2030-driven-by-novel-drug-launches-forecasts-globaldata/)

Source-IANS